Shield Therapeutics Share Discussion Threads

[z1co] 11/12/2023 07:39

Sad people after selling their trade they start to post LIES on the forum.

[the imperialist] 11/12/2023 07:33

He's made his 5% and now lives with the fear that the train will leave the station without him. Which it will.

[lr27] 11/12/2023 07:26

Not sure why you are here then...perhaps time for you to move on to another share?

[best1467] 11/12/2023 07:15

The CEO in the previous update along with the out of the blue cash raise.Major reason put forward the build a team to increase Selling price but don’t expect much progress until 2024.
A number of weeks later we are told nett selling price increased 24% before they have even recruited the team.It’s extremely confusing and increases the lack of confidence in the CEO who obviously is not in touch.
It’s yet another reason that increases the lack of confidence in the company I personally would not trust anything we get told from this CEO

[cyberbub] 09/12/2023 14:05

Delayed 1M trade, I would suggest it's a worked sell which pulled the share price down yesterday. Let's hope it's the last of the seller?

[cyberbub] 08/12/2023 17:31

It took them over 2 months to update on Q3 figures, so I'm not now expecting a Q4 update until late Feb earliest?

[tripletop1] 08/12/2023 16:33

Not sure we'll truly see a market convinced until Shield update on Q4 end Jan

Have a good Christmas all, see you in the New Year

[bolitix] 08/12/2023 15:55

I think they would hit 50k if not for festive breaks. But i emailed them about this 42k target as only then will i give some credit since their prescriber access went up 4 fold and the TVRS market was availed. I think some motivational management needs to come into play

[tripletop1] 08/12/2023 15:44

Bolitix - point well made

They really do need to step it up and you would expect it into Q4.. I'd be surprised if they didn't do a minimum of 50k

Still big numbers and impressive growth nonetheless but we are judging from initial guidance which if GM is to be believed is where they are getting back to (initial guidance)

Continued progress on GTN also into Q4 should underpin a revaluation into 2024

Ps - Repeat Writers is also encouraging.. this is what really should drive future growth.

If they do 50k in Q4 then absolutely no reason why 350k for 2024 shouldn't be comfortably surpassed with change..

Looking in the rear view mirror they've made phenomenal strides over the year (allowing for the "shooting in foot" fundraise)

[bolitix] 08/12/2023 15:21

So oold 54,033 for the year so far. Their initial target for YE23 was 125-160k sales. No way will they reach this and of course 100 sales staff need to hit 42k/Q sales for a pro-rata comparison to the 22 in 4Q23. So really they are 36% off the pace. We can argue they have 9 months behind them but those 22 were no better off this time last year!! For me less than 42k sales is unconvincing.

[tripletop1] 08/12/2023 14:19

Edison note

Shield Therapeutics — Delivering what the doctor ordered

Shield Therapeutics’ US commercialisation efforts continue to gather steam, with prescription volumes gearing up in Q323 (27,750 prescriptions, a 76% sequential growth over Q2 and higher than the combined H123 figure of 26,284) and net selling price making a strong recovery after dipping in H123 (+24% to $148/prescription). US revenues grew to $4.1m, higher than the combined H1 figure of $3.7m. First-time prescribers grew 27% q-o-q and new prescriptions were up by 87%. More encouragingly, the clinical utility of Accrufer continues to be considered favourably by prescribers, reflected in the 77% repeat writers from Q223. Management has guided for FY23 total prescriptions to be between 100k and 130k, requiring a sequential growth of 65.6% at the lower end, which we see as undemanding given the Q3 run rate and growing momentum (as the expanded salesforce gets more entrenched). We maintain our full-year estimates and continue to value the company at £390.4m.

[z1co] 08/12/2023 11:44

News from Canada not too far off:

KYE submitted a New Drug Submission ("NDS") during the first half of 2022, which was accepted by Health Canada in July 2022. The submission is currently under review by Health Canada and decision is expected in the H2 2023.

[cyberbub] 08/12/2023 11:27

Yes, I think the 100k prescriptions for 2023 is now nailed on. It's just a case of how much they exceed them by IMO. 110k would be excellent, and if it's accompanied by a further increase in GTN to say $160, then I feel that Mr Market's sentiment will start to change strongly.

[z1co] 08/12/2023 11:19

What impressed me was that the average net selling price increased 24% to $148/prescription compared to H1 2023 which was ahead of expectations.

The company is fully funded sales are increasing significantly

Q4 will be even better.

[base7] 08/12/2023 11:07

Milestone from China next year together with royalties from Canada & South Korea,together with increasing EU/UK royalties should help cash flow too next year-apart from continued growth in US sales + price increases

[ekcs] 08/12/2023 10:52

That may well be the case but it's the sentiment and therefore the expectation that they've created from their more recent IR disasters that concerns investors when they look forwards which is the point I'm making. It's going to take time for investors to develop enough trust in them to cause a reversal to the positive. The CEO could stick his hand in his pocket as well as that would only help sentiment instead of simply scooping up options that are only time delayed rather than actually having some decent performance conditions attached. Perhaps he could use some of the £350k bonus he got last year!!!

[tripletop1] 08/12/2023 10:37

Seller dumped some serious volume into yesterday's good news.. still doesn't look like they're done unfortunately

[cyberbub] 08/12/2023 10:24

They don't need another raise in the short term with the $20m loan in the kitty, and of course growing revenues. They might need another few mill in 9 months depending how the rampup goes, but that could hopefully be raised at much higher prices.

[ekcs] 08/12/2023 10:00

It's a decent update but the problem is they've managed IR so poorly over the last 2 yrs and done the opposite to what they said they'd do on a number of occasions especially with regard to fund raises that people probably expect another raise on the back of this update!!, hence the muted reaction.

[z1co] 08/12/2023 09:31

Stifel the US investment bank has a 'buy' rating on the company with 15p target price.

[z1co] 08/12/2023 09:25

Shield makes significant commercial traction with prescriptions up 76%

Published: 07:44 07 Dec 2023 GMT

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage specailist pharma company known for its Accrufer iron deficiency treatment, saw significant growth in the US market in the third quarter - pointing to increasing demand and market acceptance of the product.

Net sales for the period were US$4.1 million while the selling price reached US$148 per prescription, a 24% rise compared to the first half of the year.

Prescription numbers provided a clear picture of demand. Over 27,750 were recorded in Q3, marking 76% sequential quarterly growth. This surge is part of a broader trend, with total prescriptions exceeding 54,000 in the first nine months of 2023.

Other key metrics from the Q3 results include an 87% increase in new prescriptions and a 27% rise in the number of first-time prescribers.

Furthermore, repeat prescriptions were strong, with 77% of healthcare providers who prescribed Accrufer in Q2 continuing to prescribe it in Q3.

"Shield continues to make excellent progress on the US commercial launch of Accrufer," said chief executive Greg Madison.

"As we approach the one-year anniversary of the announcement of the Viatris agreement, I am pleased to report that the collaboration continues to deliver excellent results, based on the stand-out performance of the combined commercial team, which has produced consistent and strong sequential prescription growth and key performance indicators (KPI), which are trending towards previous guidance.

"In addition, we have made positive strides towards our goal of increasing our average net selling price and expect further progress in 2024."

[cyberbub] 07/12/2023 16:19

I've had a look at the revenue covenants in the $20M loan agreement, and the Q3 (and, barring some total disaster, Q4) covenants seem to have no problem being met. So that's a relief anyway. GLA

[parob] 07/12/2023 16:00

A close of 6.5p or above and we move pretty quickly up to 8p+ imo.The longer it ranges, the harder it breaks.

[z1co] 07/12/2023 15:55

It looks that way , NT to buy 25,000.

[parob] 07/12/2023 15:52

Feels like the seller has cleared. Fingers crossed.